Uchiyama Masaaki, Shimizu Akira, Masuda Yukinari, Nagasaka Shinya, Fukuda Yuh, Takahashi Hiroshi
Department of Ophthalmology, Nippon Medical School, Tokyo, Japan ; Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Mol Vis. 2013 Nov 1;19:2135-50. eCollection 2013.
We clarified the effects of an ophthalmic solution of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist on corneal inflammation and wound healing after alkali burn injury in rats.
After alkali exposure, either an ophthalmic solution with 0.1% pioglitazone hydrochloride (the PPARγ group) or vehicle (the vehicle group) was topically applied to the cornea until day 14. Histological, immunohistochemical, and real-time reverse transcription polymerase chain reaction analysis were performed.
After alkali injury, PPARγ expression increased, with the infiltration of many inflammatory cells. The infiltration of neutrophils and macrophages started from the corneal limbus within 6 h, and developed in the corneal center by day 7, with associated neovascularization. The accumulation of α-smooth muscle actin-positive myofibroblasts and the deposition of type III collagen were noted on day 14. The histological changes were suppressed significantly by treatment with the ophthalmic solution of the PPARγ agonist. In addition, the number of infiltrating M2 macrophages in the cornea was increased by PPARγ agonist treatment. In real-time reverse transcription polymerase chain reaction analysis, the messenger ribonucleic acid expression levels of interleukin-1β (IL-1β), IL-6, IL-8, monocyte chemoattractant protein-1, tumor necrosis factor-α, transforming growth factor beta 1, and vascular endothelial growth factor-A were decreased in the PPARγ group compared to the vehicle group in the early periods of corneal inflammation.
The ophthalmic solution of the PPARγ agonist inhibited inflammation, decreased the fibrotic reaction, and prevented neovascularization in the cornea from the early phase after alkali burn injury. The ophthalmic solution of the PPARγ agonist may provide a new treatment strategy with useful clinical applications for corneal inflammation and wound healing.
我们阐明了过氧化物酶体增殖物激活受体γ(PPARγ)激动剂眼药水对大鼠碱烧伤后角膜炎症和伤口愈合的影响。
碱烧伤后,将含0.1%盐酸吡格列酮的眼药水(PPARγ组)或赋形剂(赋形剂组)局部应用于角膜,直至第14天。进行组织学、免疫组织化学和实时逆转录聚合酶链反应分析。
碱烧伤后,PPARγ表达增加,伴有大量炎性细胞浸润。中性粒细胞和巨噬细胞在6小时内从角膜缘开始浸润,并在第7天发展至角膜中央,伴有新生血管形成。在第14天观察到α平滑肌肌动蛋白阳性肌成纤维细胞的积聚和III型胶原的沉积。PPARγ激动剂眼药水治疗可显著抑制组织学变化。此外,PPARγ激动剂治疗可增加角膜中浸润的M2巨噬细胞数量。在实时逆转录聚合酶链反应分析中,与赋形剂组相比,PPARγ组在角膜炎症早期白细胞介素-1β(IL-1β)、IL-6、IL-8、单核细胞趋化蛋白-1、肿瘤坏死因子-α、转化生长因子β1和血管内皮生长因子-A的信使核糖核酸表达水平降低。
PPARγ激动剂眼药水在碱烧伤损伤后的早期阶段可抑制角膜炎症,减少纤维化反应,并防止新生血管形成。PPARγ激动剂眼药水可能为角膜炎症和伤口愈合提供一种具有临床应用价值的新治疗策略。